Analysis of 20-year follow-up study of LVP regimen for adult acute lymphoblastic leukemia

International Journal of Hematology

Volumn 74, Issue 2, 2001, Pages 157-164

  Hatta, Yoshihiro ^a   Takeuchi, Tin ^a   Ohshima, Toshiteru ^b   Horikoshi, Akira ^a   Iizuka, Yoshikazu ^c   Kawamura, Masaaki ^d   Kanemaru, Mineo ^e   Horie, Takashi ^a  

^a NIHON UNIVERSITY   (Japan)

^b Sekishindo Hospital   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Itabashi Med Association Hospital   (Japan)

^e Higashi Jyujo Hospital   (Japan)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; L asparaginase; Ph chromosome; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; REMISSION; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0035434492     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02981999     Document Type: Article

References (22)

1. Hoelzer D, Thiel E, Ludwig WD, et al... .The German multicenter trials for treatment of acute lymphoblastic leukemia in adults. Leukemia. 1992;6:175-177.
2. Finnish Leukemia Group. Long-term survival in acute lymphoblastic leukemia in adults. Eur J Hematol. 1992;48:75-82.
3. Bassan R, Battista R, Viero P, et al. Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen. Sem Oncol. 1993; 20(suppl 8):39-46.
4. Hoelzer DF. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol din North Am. 1993;7: 139-160.
5. Durrant IJ, Richards SM. Results of Medical Research Council Trial UK ALL IX in acute lymphoblastic leukaemia in adults: report from Medical Research Council Working Party on Adult Leukaemia. Br J Haematol. 1993;85:84-92.
6. Nagura E, Kimura K, Yamada K, et al. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chem Pharmacol. 1994;33: 359-365.
7. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025-2037.
8. Mandelli F, Annino L, Rotoli B. The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. Br J Haematol. 1995;92:665-672.
9. Ueda T, Miyawaki S, Asou N, et al. Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL 90 study of the Japan Adult Leukemia Study Group. Int J Hematol. 1998;68:279-289.
10. Tanimoto M, Miyawaki S, Ino T, et al. Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan adult leukemia study group. Int J Hematol. 1998;68:421-429.
11. Finiewicz KJ, Larson RA. Dose-intensive therapy for adult acute lymphoblastic leukemia. Sem Oncol. 1999;26:6-20.
12. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
13. Bennett JM, Catovsky D, Daniel M-T, et al. Proposals for the classification of the acute leukemias. French-American-British (FAB) Co-operative Group. Br J Hematol. 1976;33:451-458.
14. Bennett JM, Catovsky D, Daniel MT, et al. The morphologic classification of acute lymphoblastic leukaemia; concordance among observers and clinical correlations. Br J Haematol. 1981;47:553-558.
15. Hoelzer D, Ludwig W-D, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87:495-508.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Peto R, Pilke ML, Armitage P, Breslow ME. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. Br J Cancer. 1977;35:1-39.
18. Cox DR. Regression models and life tables. J Royal Stat Soc B. 1972;34:187-220.
19. Linker CA, Levitt LJ, O'Dannel M, et al. Improved results of treatment of adult acute lymphoblastic leukemia. Blood. 1987;69: 1242-1248.
20. Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood.1988;71:123-131.
21. Gaynor, J, Chapman, D, Little, C. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol. 1988;6:1014-1030.
22. Kantarjian, HM, Walters, RS, Keating, MJ. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphoblastic leukemia. J Clin Oncol. 1990;8:994-1004.